Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - National Acad Sciences
Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
[PDF][PDF] Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordona, ME Kleinmana, DT Millerd, DS Neubergg… - eigerbio.com
Results Patients. Twenty-six patients with classic HGPS from 16 countries were enrolled in
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - ui.adsabs.harvard.edu
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
[HTML][HTML] Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - ncbi.nlm.nih.gov
Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
[PDF][PDF] Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordona, ME Kleinmana, DT Millerd, DS Neubergg… - researchgate.net
Results Patients. Twenty-six patients with classic HGPS from 16 countries were enrolled in
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - cir.nii.ac.jp
抄録< jats: p> Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal,
segmental premature aging syndrome caused by a mutation in< jats: italic> LMNA</jats …
segmental premature aging syndrome caused by a mutation in< jats: italic> LMNA</jats …
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller, DS Neuberg… - Proceedings of the …, 2012 - JSTOR
Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - pubmed.ncbi.nlm.nih.gov
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
[PDF][PDF] Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordona, ME Kleinmana, DT Millerd, DS Neubergg… - eigerbio.com
Results Patients. Twenty-six patients with classic HGPS from 16 countries were enrolled in
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
[PDF][PDF] Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordona, ME Kleinmana, DT Millerd, DS Neubergg… - bidmc.org
Results Patients. Twenty-six patients with classic HGPS from 16 countries were enrolled in
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …
this phase II clinical trial of lonafarnib from May through October 2007. One child with a …